Title: Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
Authors: Milder, Tamara Y.; Lin, Jialing; Pearson, Sallie‐Anne; de Oliveira Costa, Juliana; Neuen, Brendon L.; Pollock, Carol; Jun, Min; Greenfield, Jerry R.; Day, Richard O.; Stocker, Sophie L.; Brieger, David; Falster, Michael O.
Abstract: The article discusses the discontinuation of SGLT2 inhibitors (SGLT2i) in people with type 2 diabetes following hospitalization for heart failure. A study conducted in New South Wales, Australia, found that nearly 30% of SGLT2i users discontinued therapy within 90 days of discharge, with one in five remaining off treatment at 365 days. Factors such as age, hospitalization duration, number of prior hospitalizations, and chronic kidney disease were associated with higher discontinuation rates. The study highlights the importance of minimizing SGLT2i discontinuation to reduce mortality and readmission risks in this population.
Subjects: SODIUM-glucose cotransporter 2 inhibitors; ANGIOTENSIN-receptor blockers; ACE inhibitors; DIAGNOSIS related groups; TYPE 2 diabetes diagnosis; DIABETIC acidosis; DRUGSTORES; PUBLIC hospitals
Publication: Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p997
ISSN: 1462-8902
Publication type: Academic Journal
DOI: 10.1111/dom.16061

Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?

Milder, Tamara Y.; Lin, Jialing; Pearson, Sallie‐Anne; de Oliveira Costa, Juliana; Neuen, Brendon L.; Pollock, Carol; Jun, Min; Greenfield, Jerry R.; Day, Richard O.; Stocker, Sophie L.; Brieger, David; Falster, Michael O.